Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney), and glioblastoma (brain) cancer. Geographically, It operates through two reportable segments Commercial operations which include Commercial sales of Illuccix® and other products after obtaining regulatory approvals and Product development includes Developing radiopharmaceutical products for commercialisation. This segment includes revenue received from license agreements before commercialization and research and development services. It operates in Australia, the United States, Belgium, and Japan.
No Data
No Data
No Data
No Data
No Data
No Data
No Data
No Data